论文部分内容阅读
甲磺酸阿帕替尼片(艾坦~?)系口服的小分子抗血管生成靶向治疗新药,获得国家“十一五”和“十二五”计划重大新药创制专项的支持,已于2014年10月17日获得国家食品药品监督管理总局(CFDA)正式批准作为国家1.1类新药上市,成为全球第一个治疗胃癌的小分子靶向药物。为提高肿瘤医师临床诊治水平,促进临床研究的学术交流,《中国肿瘤临床》编辑部与江苏恒瑞医药股份有限公司联合举办“甲磺酸阿帕替尼治疗晚期恶性肿瘤临床有奖征文”活动。通知详情请关注本刊微信公告号(扫描文章下方二维码)查看。
Apatinib mesylate tablets (Eitan ~?) Oral small-molecule anti-angiogenesis targeted drug treatment, access to national “Eleventh Five-Year ” and “Twelve-Five ” plan major new drug creation It was officially approved by the CFDA on October 17, 2014 as a national class 1.1 new drug and became the first small molecule targeted drug in the world to treat gastric cancer. In order to improve the clinical diagnosis and treatment of oncologists and promote the academic exchange of clinical research, the editorial department of “China Oncology Clinic” and Jiangsu Hengrui Pharmaceutical Co., Ltd. jointly hold the “Clinical Prize Essay of Apatinib Mesylate for the Treatment of Advanced Malignancies” "activity. For more information, please pay attention to the publication of WeChat announcement (scan the article below the two-dimensional code) view.